Navigating Quality Assurance: The Rise of Fill/Finish Equipment Automation in 503A and 503B Compounding Pharmacies | Newsletter | Issue 13 | 2023

There is a growing emphasis on quality control in healthcare institutions, especially among those that outsource to 503A compounding pharmacies and 503B outsourcing facilities. To safeguard patient health, it is crucial to collaborate with suppliers dedicated to ensuring quality standards. One of the foremost strategies to mitigate drug contamination is incorporating semi-automated or automated equipment, technologies, and robotics. Such advancements can effectively decrease human-induced errors, enhance productivity, and streamline operations. Given these compounding pharmacies' quality assurance challenges, such technological interventions could facilitate regulatory trust and establish confidence among affiliated hospitals and clinics.

Recently, the U.S. Food and Drug Administration (FDA) has intensified scrutiny on 503B and certain 503A Compounding Pharmacies, often resulting in the issuance of Form 483s. Over previous years, an analysis of these forms has indicated persistent concerns regarding drug quality, data integrity, sterility, and preserving a controlled sterile environment. With adherence to internal processes and the integration of appropriate systems, these citations can be avoided. Starting November 1st, 2023, the newly released United States Pharmacopeia (USP 795, 797, & 800) guidelines will be enforceable. However, it should be noted that these guidelines, though aimed at reducing contamination risks, still maintain a lower standard compared to FDA-approved drugs (cGMP).

The FDA's website stipulates that while 503B outsourcing facilities are exempted from specific FDA approval prerequisites, they must adhere to current good manufacturing practice (cGMP) requirements. This, combined with the FDA's increased oversight, has led to an upswing in FDA Form 483s. Facilities receiving such citations must grapple with rectifying the identified issues and the potential reputational and financial ramifications, especially in product recall scenarios. Furthermore, suppose healthcare institutions lack confidence in their 503A/503B partners. In that case, they might opt to establish in-house drug formulation capabilities, which could result in a loss of business for external compounding pharmacies.

What about the roles of semi-automated and automated fill solutions in sterile compounding? Integrating automation and robotics in pharmaceutical compounding signifies a paradigm shift towards the future. This transition from conventional/manual methods minimizes human involvement, and many compounders are witnessing enhanced efficiency and competitiveness. For 503A and 503B facilities, these technologies bolster sterility assurance in three pivotal areas: bioburden reduction, data and process integrity, and operational flexibility. Any lapse in maintaining sterility can compromise patient health and operational productivity and lead to supply chain disruptions.

In the U.S., 503A compounding pharmacies adhere to USP guidelines, namely USP 795, 797 and USP 800, which delineate operational standards. In addition, 503B outsourcing facilities fall under federal 21 CFR Part 210 and 211 (cGMP). Equipment qualification and validation must be documented and maintained by compounding pharmacies so that by employing advanced technologies in fill/finish equipment, they are minimizing contamination risks.

Environmental monitoring is crucial in assessing contamination control efficacy, and its findings are pivotal in compounding production batch release decisions. Although most facilities constantly monitor viable contaminants, continuous non-viable particle counting is not universally practiced. From a personnel standpoint, automating repetitive tasks minimizes risks associated with precise dosing and operator fatigue.

Many FDA warning letters have incorporated data integrity components in recent years. Electronic batch records (EBR) embedded in specific systems can streamline record-keeping, improve data, and process integrity, and support compliance with regulatory requirements. The evolving nature of the compounding pharmacy sector, focusing on custom compounded drug formulations, necessitates the flexibility that semi-automated or automated equipment systems offer.

In conclusion, embracing technological advancements and ensuring strict adherence to quality standards are paramount for 503A and 503B compounding pharmacies to maintain their reputation, trust, and business viability in an increasingly regulated landscape. 

MediZap customers benefit from fill/finish automation resulting in lower sterile drug compound bioburden levels, allowing for lower E-Beam | X-Ray target dose and limits expressed in kGy even further reducing potential deleterious effects of terminal sterilization by irradiation.

Download PDF 

Older Post Newer Post